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■ Abstract Objective Nitric oxide (NO) inhibits thrombus formation, vas-
cular contraction, and smooth muscle cell proliferation. We investigated
whether NO release is enhanced after endothelial NO synthase (eNOS) gene
transfer in atherosclerotic human carotid artery ex vivo. Methods and Re-
sults Western blotting and immunohistochemistry revealed that transduc-
tion enhanced eNOS expression; however, neither nitrite production nor NO
release measured by porphyrinic microsensor was altered.In contrast, trans-
duction enhanced NO production in non-atherosclerotic rat aorta and hu-
man internal mammary artery. In transduced carotid artery, calcium-de-
pendent eNOS activity was minimal and did not differ from control
conditions. Vascular tetrahydrobiopterin concentrations did not differ be-
tween the experimental groups. Treatment of transduced carotid artery with
FAD, FMN, NADPH, L-arginine, and either sepiapterin or tetrahydro-
biopterin did not alter NO release. Superoxide formation was similar in
transduced carotid artery and control. Treatment of transduced carotid
artery with superoxide dismutase (SOD), PEG-SOD, PEG-catalase did not af-
fect NO release. Conclusions eNOS transduction in atherosclerotic human
carotid artery results in high expression without any measurable activity of
the recombinant protein. The defect in the atherosclerotic vessels is neither
caused by cofactor deficiency nor enhanced NO breakdown. Since angio-
plasty is performed in atherosclerotic arteries,eNOS gene therapy is unlikely
to provide clinical benefit.
■ Key words Nitric oxide synthase – gene therapy – adenoviral vector –
atherosclerosis – endothelium
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List of abbreviations
AdeNOS adenoviral vector for expression of
human eNOS 
AdhPAP adenoviral vector for expression of
human placental alkaline phosphatase
ADMA asymmetric dimethylarginine
BH4 tetrahydrobiopterin
CA carotid arteries
DMEM dulbecco’s modified eagle medium
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EDRF endothelium-derived relaxing factor
EGTA ethylene glycol tetraacetic acid
eNOS endothelial NO synthase
FAD flavin adenine dinucleotide
FCS fetal calf serum
FITC fluorescein isothiocyanate
FMN flavin mononucleotide
hPAP human placental alkaline phosphatase
iNOS inducible nitric oxide synthase
L-NAME N(G)-nitro-L-arginine methyl ester
MA internal mammary artery
NADPH nicotine adenine dinucleotide phos-
phate
NMA N-monomethylarginine
nNOS neuronal nitric oxide synthase
NO Nitric oxide 
NO2– nitrite
O2– superoxide
oxLDL oxidized low density lipoprotein
PEG-catalase polyethylene glycol catalase
PEG-SOD polyethylene glycol superoxide dis-
mutase
PVDF polyvinylidene fluoride
SDS-PAGE SDS-polyacrylamide gel electro-
phoresis
SOD superoxide dismutase
VSMC vascular smooth muscle cell
Introduction
Gene therapy is a promising therapeutic approach for
restenotic lesions, and for in-stent-restenosis in partic-
ular [21, 32]. Nitric oxide (NO) inhibits platelet aggrega-
tion, induces vascular relaxation, and impairs vascular
smooth muscle cell (VSMC) proliferation by specific ac-
tions on cell cycle progression [11, 12, 25]. Moreover, NO
counterregulates the induction of adhesion molecule
expression and leucocyte accumulation as well as other
inflammatory alterations occurring in atherosclerotic
arteries [3]. Therefore, overexpression of endothelial
NO synthase (eNOS) seems a reasonable concept for the
local treatment of restenotic lesions. This is particularly
plausible as balloon dilatation is performed in athero-
sclerotic vessels which exhibit reduced eNOS expression
[17].
NO formation is catalyzed by at least 3 different iso-
forms of NOS. Neuronal NOS is constitutively expressed
in neurons and some other cell types; it generates low
levels of NO. Expression of inducible NOS (iNOS) can be
induced by cytokines in many different cell types; this
isoform generates high levels of NO. Endothelial NOS is
constitutively expressed in endothelial cells and some
other cell types, and similar to nNOS, it releases low lev-
els of NO. The major reason responsible for the different
enzyme kinetics is the calcium-dependency of nNOS
and eNOS [9].
Normal function of eNOS is critically dependent on
the availability of the substrate L-arginine and several
cofactors as well. Indeed, L-arginine administration in-
creases endothelial NO synthesis in hypercholes-
terolemia [7], and tetrahydrobiopterin (BH4) infusion
restores endothelium-dependent relaxation in hyper-
cholesterolemic humans [22]. In addition, reduced NO
activity may not only be caused by diminished synthe-
sis,but also by enhanced catabolism of the radical,as the
half-life of NO is determined by its reaction with oxyhe-
moglobin and superoxide (O2–) [31]. Thus, atheroscle-
rotic arteries may have a diminished NO production be-
cause of both reduced cofactor concentration and
enhanced O2– production [18]. As treatment of resteno-
sis by gene delivery would have to be performed in such
diseased vessels, we examined whether eNOS transduc-
tion into atherosclerotic human carotid arteries (CA) ex
vivo is indeed followed by an enhanced NO production.
Methods
■ Recombinant adenovirus
An adenoviral vector for expression of human placental
alkaline phosphatase (AdhPAP) was prepared as de-
scribed [19]. The vector for expression of eNOS
(AdeNOS) was provided by Dr Stefan Janssens, Leuven,
Belgium [1]. The titer of purified viruses was deter-
mined by plaque assay on 293 cells as described [14].Vi-
ral titers ranged from 21010 to 21011 pfu/ml for all
preparations. The titer of wild type virus was deter-
mined by plaque assay on A549 cells using the same con-
ditions and was below 1 in 109 pfu/ml.
■ Cell culture, tissue culture, transduction
293 cells and A549 cells were obtained from ATCC and
cultured as recommended. CA tissue specimens were
obtained from 50 human donors undergoing end-
arterectomy. The study was reviewed by the ethics
committee of the University Hospital, and the patients
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gave their informed consent prior to inclusion in the
study. Mean age was 71±8; males: 72%; smokers: 52%;
hypercholesterolemia; 56%; hypertension: 70%; dia-
betes: 34%. 86% of patients were treated with aspirin,
64% with a statin. No difference between eNOS expres-
sion, risk factors, and specific medication was observed
in the CA specimens. All specimens exhibited macro-
scopic evidence of atherosclerotic changes (fatty
streaks, advanced lesions, atheromas). The time window
between excision of CA and beginning of gene transfer
was between 3 and 6 hours for all the experiments. Spec-
imens were cut into small pieces (55 mm) under ster-
ile conditions, while tissue pieces with large necrotic ar-
eas were avoided as the material was too friable. Internal
mammary artery tissue segments were obtained from
patients undergoing coronary artery bypass grafting.
Atherosclerotic changes were excluded by a stereo mi-
croscope (Leitz, Heerbrugg, Switzerland) at 30 magni-
fication. Rat aorta served as additional control for some
experiments. Tissue pieces were incubated with a viral
titer of 1109 pfu/ml for 2 hours at 37° and then kept in
DMEM with 10% FCS for an additional 48 hours [20].
Tissue from CA, internal mammary artery and rat aorta
was treated in an identical manner. Transduction was
confirmed by staining of AdhPAP transfected specimens
with NBT/BCIP (GIBCO) as described [23], and tissue
specimens were analyzed by a stereo microscope (Leitz,
Heerbrugg, Switzerland) at 30 magnification.
■ Western blot analysis
Western blot analysis was performed on tissue speci-
mens as described [24]. 60 μg protein were loaded per
lane, resolved by SDS-PAGE under reducing conditions,
blotted onto PVDF membranes and analyzed by chemi-
luminescence (Amersham). Equal loading of proteins
was controlled for by staining with Ponceau S as well as
by blotting for α-tubulin.
■ Immunohistochemistry
Tissue specimens were prepared as described [13].Spec-
imens were incubated with anti-eNOS monoclonal anti-
body (N30020; Transduction Laboratories, Lexington,
USA) at 4° overnight. Immunostaining was performed
with an FITC-conjugated goat anti-mouse antibody
(F479; Dako, Glostrup, Denmark) at 1:10 dilution fol-
lowed by counterstaining with Evans blue 0.1% (Merck,
Darmstadt, Germany) and mounting in glycergel
medium (Dako) [13]. Negative controls were obtained
by replacing the primary antibody with an irrelevant
anti CD18 antibody (1110; Monosan, Uden, Nether-
lands) as well as with antibodies for iNOS and nNOS
(N32020 and N31020, respectively; Transduction Labo-
ratories); positive controls were generated on human
tonsil for eNOS, porcine pituitary gland for nNOS, and
human macrophage cultures for iNOS [13].
■ Nitrite release
After transduction, tissue pieces were kept in DMEM
with 20% FCS at 37° for 48 hours. This procedure has
been shown to activate eNOS both in VSMC [25] and in
vascular tissue [26]. Tissue pieces were homogenized
and subsequently diluted in water. Quantitation of ni-
trite was performed as described [2].
■ NO release
After transduction, tissue pieces were treated as de-
scribed for nitrite measurement. NO release was stimu-
lated by 10–5 M calcium ionophore A23187, and NO was
measured by a porphyrinic microsensor as described
[28].
■ eNOS activity
Vessels were homogenized in 600 μl of a solution con-
taining 50 mM Tris pH 7.4, 250 mM sucrose, and 2 mM
EDTA. 50 μl of homogenate was incubated at room tem-
perature in 200 μl incubation medium with or without 2
mM L-NAME, containing 1 mM nicotine adenine dinu-
cleotide phosphate (NADPH), 4 mM CaCl2, 1 mM DTT,
15 μM tetrahydrobiopterin, 10 μM flavin adenine dinu-
cleotide (FAD), 10 μM flavin mononucleotide (FMN), 10
μg/ml calmodulin, 0.2 μCi 3H-arginine, and 50 μM unla-
beled L-arginine. The reaction was stopped after 1 h by
addition of HEPES (100 mM), EDTA (4 mM), EGTA (2
mM) pH 5.5 containing unlabeled amino acid markers.
For some experiments, calcium was omitted in the
buffer. Radiolabeled arginine was separated from cit-
rulline on silica gel thin-layer chromatography plates
using chloroform:methanol:NH4OH:water 1:4:2:1
vol/vol as solvent and developed with fluoraldehyde-o-
phthaladehyde reagent.The relevant bands were scraped
from the plate and counted in a scintillation counter.Cit-
rulline production was expressed as dpm citrulline/h/g
wet weight.
■ Superoxide release
After transduction, tissue pieces were kept in DMEM
with 20% FCS at 37° for 48 hours. O2– production was
measured by coelenterazine chemoluminescence as de-
scribed using a Turner Design Model TD-20/20 lumi-
nometer (Turner Designs, Sunnyvale, CA) [27]. O2– re-
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lease rate was expressed as relative light units/minute/
mg dry weight. Absolute values of O2– release were de-
termined with known quantities of xanthine and xan-
thine oxidase by the SOD inhibitable cytochrome c re-
duction using the molar extinction coefficient for
cytochrome c (21mmol/l–1 · cm–1) and expressed as
nmol/minute/mg dry weight [18].
■ BH4 concentrations
BH4 was measured in non-transduced, control vector
treated, and eNOS vector treated carotid artery as de-
scribed [10].
■ Statistics
Results represent the mean value of 5 to 8 experiments
as indicated in the text. Data are expressed as mean ±
standard error of the mean (S.E.M.) and statistical com-
parisons were performed using analysis of variance
(ANOVA).A two-tailed p value of less than 0.05 was con-
sidered to indicate a significant difference.
Results
■ Expression of eNOS
Adenoviral transduction of human CA was assessed by
human placental alkaline phosphatase (hPAP).
NBT/BCIP staining revealed the presence of functional
hPAP in CA transduced with hPAP adenovirus (hPAP),
but not with control adenovirus (ΔE1) nor under non-
transduced conditions indicating good transduction us-
ing this vector (Fig. 1A). eNOS expression in human CA
after adenoviral transduction was first examined by
Western blot analysis, which demonstrated a high ex-
pression after transduction with the eNOS adenovirus
(eNOS), while the protein was barely detectable in the
control adenovirus group (ΔE1) nor under non-trans-
Fig. 1 A. Placental alkaline phosphatase (hPAP) ex-
pression in transduced atherosclerotic human carotid
artery (CA). Intimal side observed by stereomicro-
scope at 30x magnification. NBT/BCIP staining
demonstrates hPAP in CA transduced with hPAP ade-
novirus (hPAP), but not control adenovirus (ΔE1) nor
under non-transduced conditions. B. Endothelial ni-
tric oxide synthase (eNOS) expression in CA. Western
blot analysis demonstrates eNOS in CA transduced
with eNOS adenovirus (eNOS), but not control aden-
ovirus (ΔE1) nor under non-transduced conditions. C.
eNOS expression in CA. Immunohistochemical analy-
sis demonstrates eNOS protein in CA transduced with
eNOS adenovirus (eNOS), while there is only very
faint staining with control adenovirus (ΔE1) and no
staining under non-transduced conditions (lower
row). The presence of an intact endothelium is
demonstrated by staining for von Willebrand Factor
(middle row). An H&E staining is presented as well
(upper row). Magnification 400x
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duced conditions (Fig. 1B). Immunohistochemical
analysis of eNOS expression revealed a strong signal in
endothelial and to a lesser degree in subendothelial cells
of transduced specimens. Consistent with the Western
blots, no significant staining was detected in control
adenovirus transduced tissues or in non-transduced
samples (Fig. 1C). This pattern of eNOS expression in
atherosclerotic carotid artery was observed in most
transduced specimens; however, in 2 out of 10 samples,
eNOS expression was not clearly increased as compared
to control specimens, which is consistent with the het-
erogenic morphology of the atherosclerotic tissue. Ex-
pression of iNOS and nNOS was examined in serial sec-
tions; no staining was observed in non-transduced and
transduced specimens (data not shown).
Western blotting revealed that eNOS expression was
8.75-fold higher in non-atherosclerotic human internal
mammary artery (MA) as compared side by side to ath-
erosclerotic carotid artery (p<0.05; n=4–5; Fig. 2, left
panel). Indeed, only prolonged exposure times permit-
ted to detect a signal for eNOS in the carotid artery sam-
ples.After adenoviral transduction,eNOS expression in-
creased by 10.7-fold in MA (p<0.01 for control vs. eNOS
and for ΔE1 vs. eNOS; n=5; Fig. 3, left panel) and by 9.9-
fold in CA (p<0.05 for control vs. eNOS and for ΔE1 vs.
eNOS; n=5; Fig. 3, right panel). Moreover, eNOS expres-
sion was similar in MA and CA transduced with eNOS
(p=0.55.; n=5).
■ Release of NO
NO release from CA after eNOS gene transfer was first
assessed by measuring nitrite (NO2–) tissue levels. 48
hours after transduction, the cumulative nitrite level
was 0.378±0.249 μmol/g for non-transduced condi-
tions, 0.854±0.495 μmol/g for control adenovirus (ΔE1),
and 1.110±0.696 μmol/g for eNOS adenovirus (eNOS)
(p=0.76 for control vs.eNOS; p=0.46 for control vs.ΔE1;
p=0.70 for AdΔE1 vs.AdeNOS; n=8; Fig. 4, right panel).
To compare NO release from CA with that from an arte-
rial tissue without atherosclerotic changes, a parallel set
of experiments was performed in rat aorta. In contrast
to CA, eNOS gene transfer enhanced NO release from
this tissue. Indeed, 48 hours after transduction, the ni-
trite tissue level was 0.914±0.562 μmol/g for non-trans-
Fig. 2 Endothelial nitric oxide synthase (eNOS) ex-
pression and nitric oxide (NO) release in human arter-
ies. eNOS expression (left panel) is determined by
Western blots and indicated in arbitrary densitomet-
ric units; expression is higher in internal mammary
artery (MA) as compared to atherosclerotic carotid
artery (CA). NO release (right panel) is measured by a
porphyrinic microsensor and it is higher in MA than
CA
Fig. 3 Endothelial nitric oxide synthase (eNOS) ex-
pression in transduced human arteries. Expression is
determined by Western blots and indicated in arbi-
trary densitometric units. The eNOS signal is related
to that of α-tubulin (αT) as loading control. eNOS ex-
pression is high in internal mammary artery (MA) and
atherosclerotic carotid artery (CA) transduced with
eNOS adenovirus (eNOS), while a weak signal is de-
tected in both vessels with control adenovirus (ΔE1)
or under non-transduced conditions
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duced conditions, 6.590±1.362 μmol/g for control ade-
novirus (ΔE1), and 11.112±1.493 μmol/g for eNOS ade-
novirus (eNOS) (p=0.0001 for control vs. eNOS; p<0.01
for control vs.ΔE1; p<0.05 for ΔE1 vs.eNOS; n=5; Fig. 4,
left panel). An effect of control adenovirus on NO re-
lease after eNOS transduction has been observed in
non-atherosclerotic tissue in previous studies as well
[25, 26]. To confirm that eNOS gene transfer did not af-
fect NO production in CA, the release of NO was also
measured by a porphyrinic microsensor upon stimula-
tion with 10–5 M calcium ionophore A23187.All the mea-
surements were performed within 10 seconds. NO re-
lease was similar under non-transduced conditions and
in tissue treated with control adenovirus (ΔE1) or with
eNOS adenovirus (eNOS) (p=0.82 for control vs. ΔE1;
p=0.45 for control vs. eNOS; p=0.92 for ΔE1 vs. eNOS;
n=8; Fig. 4, upper insert).
To study NO production in a non-atherosclerotic hu-
man tissue as well, NO release from transduced MA was
examined. As compared to control conditions (100%;
85±27 nM), NO production of this tissue was 89±22%
(80±40 nM) for control adenovirus (ΔE1) and
254±40% (228±106 nM) for eNOS adenovirus (eNOS)
(p<0.005 for control vs. eNOS; p<0.005 for ΔE1 vs.
eNOS; p=0.95 for control vs. ΔE1; n=4; Fig. 5A). MA NO
production under non-transduced conditions was
85±27 nM and hence much higher as compared to CA
(5±3 nM; n=9; p=0.001; Fig. 2, right panel). Again, NO
production in CA was not affected by transduction of
eNOS, while that in MA increased (Fig. 5B).
To assess whether the atherosclerotic tissue deterio-
rated during the 48 h incubation period, NO release was
compared in freshly isolated versus incubated CA and
found to be identical (fresh: 8.0±4.6 nM; incubated:
7.5±2.6 nM; n=4; p=0.93). Consistent with a minimal
NO production, eNOS activity was barely detectable in
CA; indeed, the values were several thousand fold lower
as compared to non atherosclerotic arterial tissue from
various species including humans [8, 10]. In the absence
of calcium, no enzyme activity was detected, indicating
that iNOS does not contribute to this activity. Enzyme
activity was not affected by transduction (p=n.s. for
non-transduced vs. eNOS; p=n.s. for non-transduced
vs.ΔE1; p=n.s. for ΔE1 vs.eNOS; n=5; Table).To address
whether cofactor deficiency in the atherosclerotic tissue
was responsible for the lack of enhanced NO production
after transduction, tissue concentrations of BH4 were
determined. BH4 concentrations were similar for non-
transduced (3.17±1.18 pmol/mg), ΔE1-transduced
(6.20±2.27 pmol/mg), and eNOS-transduced tissue
(7.63±4.72 pmol/mg; n=3; p=n.s.). Moreover, tissue
specimens were incubated with BH4 (10–4 M), FAD
(510–6 M), FMN (510–6 M), NADPH (510–4 M), and
L-arginine (10–4 M) for 3 hours before NO was mea-
sured. NO release was not altered in all three experi-
mental groups (non-transduced, ΔE1, eNOS) as com-
pared to conditions without cofactor addition (n=4; p
values ranging from 0.59 to 0.99; Table). Similar results
were obtained when these cofactors were present during
the 48 h period between transfection and measurement
of NO release (all values <15 nM NO; n=4; p values
ranging from 0.67 to 0.93; data not shown). Further, no
change in NO release was observed when sepiapterin in-
stead of BH4 was used (all values <15 nM NO; n=2; data
not shown).
■ Release of O2–
To analyze whether increased O2– generation in trans-
duced CA could lead to enhanced catabolism of NO, the
release of O2– was measured by coelenterazine chemolu-
minescence. O2– production was 0.245 nmol/min/mg
dry weight for non-transduced conditions, 0.335
nmol/min/mg dry weight for control adenovirus (ΔE1),
and 0.254 nmol/min/mg dry weight for eNOS aden-
Fig. 4 Nitric oxide (NO) and superoxide (O2–) pro-
duction in transduced atherosclerotic human carotid
artery (CA). Nitrite production is similar in CA trans-
duced with eNOS adenovirus (eNOS) as compared to
control adenovirus (ΔE1) and non-transduced condi-
tions. In contrast, nitrite production is significantly
higher in rat aorta transduced with eNOS as com-
pared to ΔE1 and non-transduced conditions. Nitric
oxide (NO) production is shown in the upper insert
and is similar in CA transduced with eNOS as com-
pared to ΔE1 and non-transduced conditions. Super-
oxide (O2–) production is shown in the lower insert
and is also similar in CA transduced with eNOS as
compared to ΔE1 and non-transduced conditions
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ovirus (eNOS) (p=0.97 for non-transduced vs. eNOS;
p=0.59 for non-transduced vs. ΔE1; p=0.71 for ΔE1 vs.
eNOS; n=5; Fig. 4 lower insert). To address whether su-
peroxide generated in the atherosclerotic tissue reacted
with NO, the porphyrinic microsensor measurement
was repeated in the presence of superoxide dismutase
(SOD; 25 U/ml) or polyethylene glycol superoxide dis-
mutase (PEG-SOD; 300 U/ml). NO release was not al-
tered in all three experimental groups (non-transduced,
ΔE1, eNOS) as compared to conditions without addition
of SOD or PEG-SOD (p values ranging from 0.45 to 0.99;
n=5; Table). To assess whether H2O2 was involved in NO
breakdown,the microsensor measurement was repeated
in the presence of PEG-catalase (1000 U/ml). NO release
was not altered in all three experimental groups (non-
transduced, ΔE1, eNOS) as compared to conditions
without addition of PEG-catalase (p values ranging from
0.43 to 0.95; n=4; Table).As a positive control for the ac-
tion of PEG-SOD and PEG-catalase preparations, the ef-
fect of 300 U/ml of PEG-SOD and 1000 U/ml of PEG-
catalase on conversion of dichlorodihydrofluorescein
diacetate to dichlorodihydrofluorescein was deter-
mined. PEG-SOD reduced the conversion induced by 1
mM SIN-1 to 26±0.5% of control (p<0.001; n=6). PEG-
catalase also inhibited conversion induced by 1 mM
H2O2 (54±0.6% of control; p<0.0001; n=6).
Discussion
This study demonstrates that adenoviral transduction
of atherosclerotic human CA results in marked eNOS
expression without enhancing NO release, indicating
that the recombinant enzyme is dysfunctional in ather-
Fig. 5 Release of nitric oxide (NO) in transduced hu-
man arteries measured by porphyrinic microsensor.
A. NO release is higher in internal mammary artery
(MA) transduced with endothelial nitric oxide syn-
thase (eNOS) adenovirus as compared to control ade-
novirus (ΔE1) or to control conditions. Left panel:
original recording; right panel: average values of 4 in-
dependent experiments. B. NO release is higher in
MA as compared to atherosclerotic carotid artery un-
der nontransduced conditions (left panel), after treat-
ment with ΔE1 (middle panel), and after transduc-
tion with eNOS (right panel)
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osclerotic human vessels. Expression of the transduced
genes in CA was observed in both endothelium and
subendothelial cells. After eNOS transduction, VSMC
and adventitial fibrocytes can release NO [8, 25]; thus,
medial and adventitial cells may contribute to NO re-
lease in transduced vessels. Therefore, endothelial dam-
age or even denudation during PTCA is not a reason to
refrain from eNOS gene transfer. However, the lack of
NO release indicates that eNOS gene transfer is not a
reasonable gene therapy strategy for restenosis or ather-
osclerotic vascular disease.
A higher eNOS expression in transduced atheroscle-
rotic CA as compared to control tissue was observed in
8 out of 10 samples. In the other two samples, no clear
increase in eNOS expression was present as compared to
control. Hence, transfection of atherosclerotic CA is
somewhat variable, presumably due to its morphologi-
cal heterogeneity. Nevertheless, most of the samples ex-
hibited a higher eNOS expression as compared to con-
trol. Therefore, the missing increase in NO release in all
the transduced samples can not be explained by vari-
ability of transfection. NO production after eNOS trans-
duction was determined by both nitrite formation and
NO release. Neither method detected an enhanced NO
production in transduced CA as compared to control
tissue. Rat aorta and human internal mammary artery
served as non-atherosclerotic controls for NO formation
after eNOS transduction. These controls were chosen
because of the obvious difficulties to obtain non-ather-
osclerotic human CA. Experiments were performed in
parallel with those in CA and revealed both an enhanced
eNOS expression and NO production after eNOS trans-
duction, demonstrating that overexpression of eNOS
enhances NO release only in non-atherosclerotic tissue;
therefore, similar to endogenous eNOS, the transduced
enzyme seems to be dysfunctional in atherosclerotic tis-
sue. The lack of NO release is not only consistent with
dysfunction of eNOS, but also with absence of iNOS ex-
pression in the CA tissue; as the specimens originated
from long-standing lesions with presumably stable
plaques, inflammation probably does not play a major
role in these lesions any longer.
In the rat aorta, the control adenovirus had some ef-
fect on nitrite formation, suggesting that the vector in-
duces the endogenous enzyme. Consistent with this in-
terpretation, there was a very faint staining for eNOS in
the ΔE1 transduced CA. As nitrite formation in the lat-
ter was neither altered by ΔE1 nor eNOS adenovirus,
atherosclerosis may induce a similar functional defect of
both the endogenous and the recombinant enzyme.
However, the control vector did not have any effect on
NO formation as determined by the porphyrinic mi-
crosensor in the human internal mammary artery. This
observation offers the alternative explanation that the
effect of ΔE1 on nitrite formation does not depend on
NO or, with lower probability, that it is influenced by the
type of species or vessel involved.
Activity of eNOS in CA was determined by a highly
sensitive modification of the citrulline assay and was al-
most undetectable both under control conditions and
after eNOS transduction. Indeed, the values were several
thousand fold lower as compared to non-atherosclerotic
arterial tissue from various species including humans
[5, 16]. This observation demonstrates that eNOS activ-
ity is not enhanced after transduction and is consistent
with the minimal NO release from the atherosclerotic
tissue. For catalysis of NO formation from L-arginine,
eNOS requires several cofactors. Indeed, FAD and FMN
are necessary for electron transport from NADPH to
oxygen, while BH4 is required for efficient generation of
NO from reduced oxygen and L-arginine. Deficiency of
these cofactors may hamper the function of the endoge-
nous as well as the recombinant enzyme. In fact, athero-
sclerotic vessels contain lower cofactor concentrations
and release less NO as compared to normal vessels, and
cofactor infusion can improve NO formation [7, 22, 31].
Hence, BH4 concentrations in CA after eNOS transduc-
tion were determined. Concentrations of the cofactor
did not differ in transduced as compared to control tis-
sue. Further, NO release from CA after eNOS transduc-
tion was examined in the presence of cofactor supple-
mentation. Under these conditions, however, NO release
did not differ in transduced as compared to control tis-
sue. Although some degradation of cofactors in culture
can not be excluded, these data suggest that cofactor de-
ficiency alone can not account for the dysfunction of the
recombinant enzyme. Hence, the lack of eNOS activity
in transduced atherosclerotic tissue must be related to
other mechanisms as well. Indeed, it is conceivable that
the presence of oxidized LDL in the atherosclerotic tis-
sue may impair signal transduction activation of eNOS;
Table Activity of endothelial nitric oxide synthase (NOS) and release of nitric ox-
ide (NO) in the presence of cofactors, superoxide dismutase (SOD; 25 U/ml), PEG-
SOD (300 U/ml), PEG-catalase (1000 U/ml) in transduced atherosclerotic human
carotid artery (CA). NOS activity was determined by citrulline assay, NO production
by porphyrinic microsensor. The cofactors L-arginine (10–4 M), BH4 (10–4 M), FAD
(5x10–6 M), FMN (5x10–6 M), NADPH (5x10–4 M) were added for 30 minutes prior
to measurement. All the treatments did not significantly improve NOS activity or
NO release (p=n.s.)
Parameter Control ΔΔE1 eNOS
NOS activity (pmol NO/h/g protein) 4.6±4.6 27.1±10.3 24.3±14.1
NO release without cofactors (nM) 5.0±5.0 5.8±3.9 10.8±4.0
NO release with cofactors (nM) 13.0±6.0 8.3±5.0 5.0±5.0
NO release without SOD (nM) 5.2±5.2 2.0±2.0 7.8±5.2
NO release with SOD (nM) 5.2±5.2 9.8±6.0 5.2±5.2
NO release without PEG-SOD (nM) 4.0±2.3 6.6±4.2 8.5±3.1
NO release with PEG-SOD (nM) 6.6±3.8 4.0±2.3 10.1±3.5
NO release without PEG-catalase (nM) 5.3±1.8 1.8±1.8 2.8±2.8
NO release with PEG-catalase (nM) 5.0±5.0 8.3±3.1 3.5±3.5
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furthermore, competitive inhibitors of eNOS such as
ADMA may be synthesized in the endothelium causing
decreased eNOS activity [4].
In case of suboptimal BH4 concentrations, uncou-
pling of eNOS occurs, and the enzyme itself becomes a
source of O2–. Hence, the lack of an increase in NO pro-
duction after eNOS transduction may be related to in-
creased O2– formation resulting in NO catabolism.
Therefore, O2– generation in CA was determined. O2– re-
lease did not differ in eNOS transduced tissue as com-
pared to control conditions, indicating that enhanced
NO catabolism is not a probable reason for the unaltered
NO release after transduction, and supporting the inter-
pretation that cofactor deficiency can not be the sole
reason for the dysfunction of recombinant eNOS. Con-
sistent with these observations, NO production re-
mained identical in the presence of SOD and PEG-SOD.
Similarly, PEG-catalase did not affect the formation of
NO, indicating that NO catabolism by H2O2 can be ex-
cluded as a reason for the unaltered NO release after
transduction as well.
In theory, eNOS gene transfer is a very reasonable
therapeutic strategy for vascular disease, as NO does not
only inhibit VSMC proliferation,but also impairs throm-
bus formation eliminating a major source of mitogens
for VSMC, and interferes with adhesion molecule ex-
pression as well as leucocyte invasion [3, 12]. In addi-
tion, expression of eNOS is reduced in atherosclerotic
tissue, demanding substitution by a recombinant en-
zyme [17]. For the treatment of restenosis, however,
eNOS gene transfer is unlikely to provide clinical bene-
fit; such vessels are severely atherosclerotic, and, accord-
ing to our data, transduction would result in expression
of an inactive enzyme. Since eNOS gene transfer has
been described to reduce vascular smooth muscle cell
proliferation [6] and restenosis in a pig and a mouse
model [15,29,30], the inactivity of recombinant eNOS in
the human CA is surprising; however,differences in gen-
der, in the degree of atherosclerosis,and/or in the patho-
genesis of atherosclerosis may well account for the dif-
ferent activity of recombinant eNOS in these models and
the human tissue. Thus, transduction of a gene can re-
sult in unexpected features in the respective human tis-
sue, indicating that ex vivo studies with the relevant tis-
sue should be performed before starting clinical trials.
In contrast to restenosis, coronary artery bypass graft
disease still represents a promising target for eNOS gene
transfer. Indeed, the saphenous vein is not atheroscle-
rotic when implanted as bypass graft. Moreover, eNOS
transduction inhibits biological features of bypass graft
disease in the human saphenous vein ex vivo [26].
Therefore, in its current state, successful application of
gene transfer technology for treating vascular diseases
requires a specifically tailored strategy, which does not
only take into account efficieny of transduction and du-
ration of expression, but also the biological characteris-
tics of the respective human tissue.
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